Interpreting change from patient reported outcome (PRO) endpoints: patient global ratings of concept versus patient global ratings of change, a case study among osteoporosis patients by unknown
RESEARCH Open Access
Interpreting change from patient reported
outcome (PRO) endpoints: patient global
ratings of concept versus patient global
ratings of change, a case study among
osteoporosis patients
Annabel Nixon1, Helen Doll2, Cicely Kerr3, Russel Burge4 and April N. Naegeli4*
Abstract
Background: Regulatory guidance recommends anchor-based methods for interpretation of treatment effects
measured by PRO endpoints. Methodological pros and cons of patient global ratings of change vs. patient global
ratings of concept have been discussed but empirical evidence in support of either approach is lacking. This study
evaluated the performance of patient global ratings of change and patient global ratings of concept for
interpreting patient stability and patient improvement.
Methods: Patient global ratings of change and patient global ratings of concept were included in a psychometric
validation study of an osteoporosis-targeted PRO instrument (the OPAQ-PF) to assess its ability to detect change
and to derive responder definitions. 144 female osteoporosis patients with (n = 37) or without (n = 107) a recent
(within 6 weeks) fragility fracture completed the OPAQ-PF and global items at baseline, 2 weeks (no recent
fracture), and 12 weeks (recent fracture) post-baseline.
Results: Results differed between the two methods. Recent fracture patients reported more improvement
while patients without recent fracture reported more stability on ratings of change than ratings of concept.
However, correlations with OPAQ-PF score change were stronger for ratings of concept than ratings of
change (both groups). Effect sizes for OPAQ-PF score change increased consistently with level of change in
ratings of concept but inconsistently with ratings of change, with the mean AUC for prediction of a
one-point change being 0.72 vs. 0.56.
Conclusions: This study provides initial empirical support for methodological and regulatory
recommendations to use patient global ratings of concept rather than ratings of change when interpreting
change captured by PRO instruments in studies evaluating treatment effects. These findings warrant being
confirmed in a purpose-designed larger scale analysis.
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Background
As with all outcome measures used to evaluate the im-
pact of a medical product, one of the biggest challenges
for patient reported outcome (PRO) endpoints is how to
interpret the change in scores between two time points
or the difference in change scores between treatment
groups [1]. Most PRO instruments comprise one or
more scales, with items aggregated into multi-item
scales and scores for each individual often considered at
group-level. Interpretation of PRO data requires an un-
derstanding of potential complexities associated with
self-report, comparison of different response scales, and
of psychometrics in general [1]. Further, the statistical
significance of any score change over time does not
guarantee that differences are clinically meaningful, with
statistical significance sometimes achieved for notably
small score changes, particularly if the sample size is
large [2, 3].
The history of debate over the methods for interpret-
ing change in longitudinal studies has been recently
summarised by Wyrwich and colleagues [4]. The debate
heightened during the consultation period following
publication of the Food and Drug Administration (FDA)
draft guidance [5] and continued after the publication of
the FDA final guidance report for Industry PRO mea-
sures [2], with Burke and Trentacosti [6] offering further
considerations beyond those provided in the final FDA
guidance. A key shift in approach over this period has
been a move away from using the group level minimum
important difference (MID) to evaluate treatment bene-
fit, the focus of much of the prior efforts to develop
values to aid interpretation of change [4], to using the
patient level responder definition. The MID is the
amount of difference between treatment groups in the
change observed in a PRO measure that can be inter-
preted as a treatment benefit [5], whereas the responder
definition is the amount of change in an individual
patient which can be interpreted as a treatment benefit:
the proportions of individuals in each trial arm who meet
this threshold (or indeed a variety of thresholds) for PRO
score change are compared between treatment arms.
Empirical approaches for defining both the MID and
the responder definition can be either anchor-based or
distribution-based. The FDA has stated a preference for
anchor-based rather than distribution-based approaches
for establishing the responder definition [2]. Anchor-
based methods explore the association between the PRO
instrument and a related external anchor, where differ-
ent types of anchors can be utilised. Distribution-based
approaches evaluate score change in the context of score
variability e.g. ½ standard deviation, or 1 standard error
of measurement (SEM). Typically, distribution-based ap-
proaches have been used to establish the MID. Where
anchor-based approaches have been used, this tends to
be termed minimum clinically important difference
(MCID), although these terms have been used inter-
changeably. The FDA considers distribution-based ap-
proaches to be supportive of anchor-based approaches,
providing the minimum value for a responder definition
derived from anchor-based methods. This is because a
responder definition must be at least large enough to be
beyond a score change that might reasonably be ex-
pected by chance alone [2].
The FDA PRO Guidance [2] makes specific reference
to the use of patient ratings of change as an anchor, for
which the patient rates how much change they have ex-
perienced on a single-item scale. Importantly, this scale
must relate conceptually to the content of the PRO in-
strument that will be used to evaluate treatment benefit
(e.g., pain or physical function), an approach originally
developed by Jaeschke et al. [7] and the most commonly
reported anchor-based method. This single-item scale
has response options ranging from deterioration through
to improvement in the concept of interest, with a mid-
point of no change. The corresponding PRO score
change for patients who have rated a certain, such as a
small or moderate, level of change is then taken to indi-
cate a meaningful PRO score change for use in PRO
score interpretation and to identify responders (i.e.,
those whose level of PRO score change has have met the
responder definition). There are, however, concerns
about the use of patient global ratings of change, specif-
ically concerning recall bias associated with retrospective
assessments over long periods of time [8] and for dis-
eases with a high level of symptom variability across
short periods of time, such as irritable bowel syndrome
[6]. Thus, the FDA has more recently recommended the
use of patient global ratings of concept items, for which
the patient rates their current state on a relevant PRO
concept at each key time-point, with the change in glo-
bal concept ratings between the time-points calculated
for analysis [6].
Whilst methodological pros and cons of patient glo-
bal ratings of change versus change in patient global
ratings of concept have been discussed [4], empirical
evidence for the relative benefits of each approach is
lacking. This study compares the statistical perform-
ance of two anchor based approaches, patient global
rating of change and patient global rating of concept,
for interpreting patient stability and patient improvement
using data collected for the psychometric validation of an
osteoporosis-targeted PRO, the Osteoporosis Assessment
Questionnaire – Physical Function (OPAQ-PF).
Methods
The design, sample and procedures of the full OPAQ-PF
psychometric validation study are reported in detail
elsewhere [9].
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Design
Post-menopausal women aged ≥50 years, diagnosed with
moderate-to-severe osteoporosis, with or without a re-
cent (within six weeks prior to baseline) fragility frac-
ture, were recruited through ten clinical sites in the US.
These patients completed the OPAQ-PF and global
items at baseline (global concept), 2 weeks (no recent
fracture, global concept and change) and 12 weeks (re-
cent fracture, global concept and change) post-baseline
(Fig. 1). Participants who had not experienced a recent
fracture were expected to experience stability in their
ability to perform daily activities of physical functioning
at week two while those with recent osteoporotic frac-
ture were expected to experience change, specifically im-
provement, in their ability to perform daily activities of
physical functioning between baseline and week 12. In-
stitutional review board (IRB) approval was obtained for
the study (Protocol OXO2550; Independent Investiga-
tional Review Board, Inc.: 21 October 2011).
Measures
The OPAQ-PF [9, 10] is designed to evaluate the partici-
pant’s ability to perform their daily activities of physical
function during the past seven days. The instrument
covers mobility (5 items), physical positions (6 items)
and transfers (4 items). Items are rated on a six-point
Likert response scale ranging from ‘no difficulty’ [score
0] to ‘completely avoided doing this’ [score 5] (subse-
quently modified to ‘unable to do’; see discussion). All
15 items are reverse scored, summed and transformed
to a 0–100 scale to provide a total score, where 0 indi-
cates the most difficulties and 100 no difficulties. A
qualitative study with 32 participants demonstrated con-
tent validity of the OPAQ-PF in post-menopausal
women who had, and had not, previously sustained a
fracture [9]. A prospective study of 144 postmenopausal
women with moderate to severe osteoporosis demon-
strated that the OPAQ-PF was: unidimensional; had
good internal consistency (α = 0.974); good test-retest
reliability (ICC = 0.993); differentiated between patients
with/without a recent fracture and by severity of
osteoporosis; and correlated strongly with hypothesized-
related scales and performance based measures (r ≥ 0.6,
p < 0.001) [10].
Three patient global ratings of concept items (ratings
of concept) and three patient global ratings of change
items (ratings of change) were developed to evaluate the
ability of the OPAQ-PF to detect change and to evaluate
interpretation of change [4]. These ratings reflected the
three content areas of the OPAQ-PF (mobility, physical
positions and transfers). Ratings of concept items were
self-completed by participants to reflect overall difficulty
Fig. 1 Schedule of assessments
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in the last seven days in these areas due to osteoporosis.
For example, for mobility participants were asked
“Overall, how much difficulty have you had with mobil-
ity (e.g. walking or climbing stairs) due to your osteopor-
osis in the last 7 days?” The participant rated difficulty
on a five-point scale ranging from ‘no difficulty’ (0),
through ‘a little difficulty’ (1), ‘some difficulty’ (2), ‘mod-
erate difficulty’ (4), to ‘severe difficulty’ (5). Ratings of
change items were self-completed by participants who
were asked to rate their overall change in the same three
areas since the last study visit. For example, the mobility
rating of change item asked “Overall, compared to your
last visit, how has your mobility (e.g. ability to walk or
climbing stairs) due to your osteoporosis changed?”
Participants rated each item on a seven-point scale ran-
ging from ‘much better’ (3), through ‘moderately better’
(2), ‘a little better’ (1), ‘no change’ (0), ‘a little worse’ (−1),
‘moderately worse’ (−2), to ‘much worse’ (−3).
Procedures
Full study procedures are reported elsewhere [10]. Par-
ticipants completed the OPAQ-PF and the three ratings
of concept at baseline. Participants without a recent frac-
ture completed the OPAQ-PF, the three ratings of con-
cept, and three ratings of change two weeks (median 14
days, Inter-Quartile Range (IQR) 14–18 days) after base-
line, over which time change was not expected. Partici-
pants with a recent fracture attended a visit at 12 weeks
(median 12, IQR 12.0-12.7) post-baseline and completed
the OPAQ-PF, the three ratings of concept and three
ratings of change items at each follow-up visit (Fig. 1).
Improvement was expected among recent fracture
participants during this time period. Participants with a
recent fracture also attended a visit at 24 weeks post-
baseline [10]; these data are not used in the current
analysis because the rating of change items asked the pa-
tients to compare their functioning with the previous
visit (week 12) rather than baseline.
Statistical analysis
The change on each rating of concept was calculated at
week two (no recent fracture group) and week 12 (recent
fracture group) relative to the score at baseline. In order
to evaluate possible recall bias, ratings of change were
correlated with ratings of concept completed at the same
and previous time-point using Spearman’s correlation
coefficient (rs). Retrospective recall is considered un-
biased if ratings of change are positively correlated with
follow-up scores and negatively correlated with baseline
scores [8], and to an equal degree [11]. Correlations
were expected to be at least moderate at ≥ |0.30| [12].
Change scores in OPAQ-PF at weeks two and 12 were
calculated and OPAQ-PF score changes correlated with
patient global ratings of concept and patient global
ratings of change scores (rs). Mean and median OPAQ-
PF change scores were compared between participants
in each patient-rated level of change and change in pa-
tient ratings of concept group using ANOVA and
Kruskal-Wallis (K-W) tests. Tests for linear trend (and
departures from linearity) were conducted within the
ANOVA. Cohen’s d effect size for OPAQ-PF change
(mean change / baseline standard deviation, SD; [12])
were calculated at each level of rating of change and
change in ratings of concept.
Receiver operator characteristic (ROC) curves were
used to identify the OPAQ-PF change score which best
distinguishes individual patients who improved to a spe-
cified extent from those who did not (the ‘best cut point’,
BCP) [13, 14]. ROC curves were plotted for participants
reporting at least a one unit improvement on the specific
ratings of concept and ratings of change at weeks 2
(no recent fracture group) and 12 weeks (recent frac-
ture group). ROC curves plot sensitivity, the propor-
tion of true ‘positives’ detected (y-axis) against 1-
specificity, the proportion of true ‘negatives’ detected
(x-axis) for all possible cut-points of the OPAQ-PF.
The ‘best cut point’ is identified as the test value
which maximises the sum of sensitivity and specifi-
city, i.e. the test value associated with the point clos-
est to the top left hand corner of the ROC space.
The area under the curve (AUC) can also be calcu-
lated: the closer it is to 1.0, the better the differenti-
ation of the scale. Therefore, the greater the AUC,
the greater the ability of the OPAQ-PF to differentiate
those who reported change from those who did not.
Statistical significance throughout was taken at the 5 %
level (p < 0.05).
Results
Sample
The overall sample (n = 144), comprised 107 patients
without recent fracture and 37 recent fracture patients.
Baseline sample characteristics are presented in Table 1
(further details reported elsewhere [10]).
Patient ratings of change and change in global concept
At week 2, the no recent fracture patients were more
likely to report stability (no change) on the ratings of
change than on the ratings of concept (i.e., difference in
ratings of concept between time-points = 0): mobility
n = 79 (75 %) vs. n = 72 (69 %), physical positions n = 81
(77 %) vs. n = 65 (62 %), transfers n = 88 (84 %) vs. n = 62
(60 %) (Fig. 2). At week 12, the recent fracture patients
were generally less likely to report stability or a small
degree of improvement on the ratings of change, being in-
stead much more likely to report feeling’much better’ vs.
an improvement of 3 or more on the ratings of concept:
mobility n = 12 (35 %) vs. n = 2 (6 %), physical
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Table 1 Participant characteristics















Did not complete high school 5 (4.7 %) 3 (8.1 %) 8 (5.6 %)
High school 31 (29.0 %) 12 (32.4 %) 43 (29.9 %)
Some college 33 (30.8 %) 12 (32.4 %) 45 (31.2 %)
College degree 25 (23.4 %) 4 (10.8 %) 29 (20.1 %)
Graduate degree 13 (12.1 %) 6 (16.2 %) 19 (13.2 %)
Ethnicity
Asian 2 (1.9 %) 0 (0 %) 2 (1.4 %)
Black 1 (0.9 %) 3 (8.1 %) 4 (2.8 %)
Hispanic 4 (3.7 %) 2 (5.4 %) 6 (4.2 %)
White or Caucasian 100 (93.5 %) 32 (86.5 %) 132 (91.7 %)
Employment
Employed full time 14 (13.1 %) 6 (16.2 %) 20 (13.9 %)
Employed part time 8 (7.5 %) 0 (0 %) 8 (5.6 %)
Retired 64 (59.8 %) 21 (56.8 %) 85 (59.0 %)
Unemployed 1 (0.9 %) 0 (0 %) 1 (0.7 %)
Looking after home/family 11 (10.3 %) 2 (5.4 %) 13 (9.0 %)
Permanently unable to work 7 (6.5 %) 7 (18.9 %) 14 (9.7 %)
Other 2 (1.9 %) 1 (2.7 %) 3 (2.1 %)
Disease duration
[min-max, years]
6.83 (4.80) n = 94
[0.45 – 19.8]
8.02 (6.75) n = 25
[0–30.6]
7.08 (5.26) n = 119
[0 – 30.6]
Time (months) since most recent fracture
[min-max, months]
123.9 (193.5) n = 53
[1.97 - 703.8]
0.75 (0.41) n = 37
[0–1.35]
73.3 (160.0) n = 90
[0–704.6]
Medication
Calcium 69 (64.5 %) 24 (64.9 %) 93 (64.6 %)
Vitamin D 73 (68.2 %) 24 (64.9 %) 97 (67.4 %)
Bisphosphonates 68 (63.6 %) 12 (32.4 %) 80 (55.6 %)
Other 29 (27.1 %) 9 (24.3 %) 38 (26.4 %)
Pain medicationsa 64 (59.8 %) 28 (75.7 %) 92 (63.9 %)
Upper/lower limb impediments
Osteoarthritis 42 (39.3 %) 14 (37.8 %) 56 (38.9 %)
Hip 22 (20.6 %) 3 (8.1 %) 25 (17.4 %)
Knee 32 (29.9 %) 10 (27.0 %) 42 (29.2 %)
Ankle 5 (4.7 %) 3 (8.1 %) 8 (5.6 %)
Shoulder 11 (10.3 %) 3 (8.1 %) 14 (9.7 %)
Wrist/hand 25 (23.4 %) 9 (24.3 %) 34 (23.6 %)
Other upper limb 12 (11.2 %) 3 (8.1 %) 15 (10.4 %)
Other lower limb 14 (13.1 %) 6 (16.2 %) 20 (13.9 %)
No upper/lower limb impediment 57 (53.3 %) 20 (54.1 %) 77 (53.5 %)
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Table 1 Participant characteristics (Continued)
OPAQ-PF scores (Total 0–100)b
Mean (SD) 82.2 (21.1) 57.0 (26.1) 75.7 (24.9)
Median (IQR) 92.0 (69.3–100) 58.7 (37.3–78.7) 83.3 (57.7–98.7)
Min, max 28, 100 5.33, 100 5.33, 100
N (%) max 31 (29.0 %) 1 (2.7 %) 32 (22.2 %)
aincludes 8 patients who reported taking pain medications their clinicians were unaware of and 5 patients who did not report taking medications prescribed by
their clinicians
blower scores indicate greater impairment
Fig. 2 Patient % reporting each mobility, physical positions, and transfers global change/difference in concept rating at each assessment. Note:
Numbers in brackets are the number of subjects in each response category
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positions n = 12 (35 %) vs. n = 3 (9 %), transfers n = 12
(36 %) vs. n = 2 (6 %) (Fig. 2).
Patient ratings of change at 2 and 12 weeks were at
least moderate and correlated significantly with patient
ratings of concept at the same assessment, but were
smaller and (at 12 weeks) generally not significantly cor-
related with ratings of concept at the previous assess-
ment. Thus, the correlations between 2-week ratings of
change and concept were: mobility 0.322 (p < 0.001),
physical positions 0.328 (p < 0.001), transfers 0.300
(p = 0.002); whereas correlations between 2-week
ratings of change and baseline ratings of concept
were: mobility 0.216 (p = 0.027), physical positions
0.258 (p = 0.008), transfers 0.200 (p = 0.041). Correla-
tions between 12-week ratings of change and concept
were: mobility 0.699 (p < 0.001), physical positions
0.694 (p < 0.001), and transfers 0.481 (p = 0.005);
whereas correlations between 12-week ratings of change
and baseline ratings of concept were 0.451 (p = 0.007),
0.271 (p = 0.121), and −0.037 (p = 0.843) respectively.
Correlation with OPAQ-PF score change
Correlations with the OPAQ-PF score change were
stronger for change in ratings of concept (Table 2) than
ratings of change (Table 3). At week 2, correlations for
the change in the ratings of concept items were 0.152 (p
= 0.122) for Mobility, 0.247 (p = 0.011) for Physical Posi-
tions and 0.318 (p < 0.01) for Transfers, compared with
−0.082 (p = 0.405) for Mobility, 0.042 (p = 0.673) for
Physical Positions, and 0.028 (p = 0.777) for Transfers
ratings of change. At week 12, correlations for the
change in ratings of concept items were 0.749 (p < 0.01)
for Mobility, 0.464 (p < 0.01) for Physical Positions and
0.503 (p < 0.01) for Transfers compared with 0.322
(p = 0.064) for Mobility, 0.447 (p < 0.01) for Phys-
ical Positions, and 0.426 (p = 0.013) for Transfers
ratings of change.
OPAQ-PF score changes by patient ratings of change and
change in global concept
In terms of comparisons of OPAQ-PF change scores be-
tween the categories of ratings of concept (Table 2) and
ratings of change (Table 3), while there were significant
differences in scores for two of the six evaluations of
global ratings of concept (Transfers at week 2, p < 0.05,
and Physical positions at week 12, p < 0.01) and global
ratings of change (Mobility at week 2 and Physical Posi-
tions at week 12, both p < 0.05), the associations were
more likely to show significant linearity for the ratings of
concept: Physical Positions at week 2, Transfers at week
2, Mobility at week 12 (all p < 0.05), Physical Positions
at week 12, Transfers at week 12 (both p < 0.01); com-
pared with the ratings of change: Transfers at week 12
(p < 0.05) and Physical Positions at week 12 (p < 0.01).
Effect sizes
In line with the patterns shown for linearity, effect sizes
for change in OPAQ-PF score at each time point were
notably irregular across categories of ratings of change
(Table 3) while generally increasing consistently by level
of change for ratings of concept (Table 2 (and Additional
file 1: Figure S1)). For example, at week 12, effect sizes
for OPAQ-PF score change increased from 0.10 in those
reporting no change in the Physical Positions concept,
to 0.82 in those reporting a 1-point change, 3.48 in those
reporting a 2-point change, and 4.97 in those reporting a
3 to 4-point change. In terms of Physical Positions rat-
ings of change, OPAQ-PF effect sizes were 0.30 ‘no
change’, 1.11 ‘a little better’, 6.4 ‘moderately better’, and
0.86 ‘much better’.
ROC curves
ROC curves were obtained for the OPAQ-PF based on
the ratings of concept and ratings of change for minimum
of a one point change (Additional file 2: Figure S2). The
characteristics of the ROC curves are summarised in
Table 4 showing the AUC (with 95 % confidence intervals)
and best OPAQ-PF cut-points for at least a one point im-
provement on the ratings of concept and rating of change
items at weeks 2 and 12. The OPAQ-PF showed good
ability to differentiate patients who had/had not shown a
one point improvement on the ratings of concept/ratings
of change, although disparities were found between the
two methods with the ratings of concept generally being
associated with greater predictive power of the OPAQ-PF.
The ratings of change results at each time point had an
overall mean AUC of 0.56 (range 0.37-0.78), with the
AUC being less than 0.5 for each of the week 2 ROC
curves, showing it is not predictive. For the ratings of con-
cept, the mean AUC was 0.73 (range 0.60-0.87), and all
were ≥0.5 and therefore predictive. The ratings of concept
had slightly worse sensitivity but better specificity com-
pared with the ratings of change (mean sensitivity over all
time points 0.68, range 0.48-0.88 vs. mean 0.76, range
0.71-0.79; specificity mean 0.66, range 0.23-0.79 vs. mean
0.49, range 0.27-0.73), with the greater sensitivity of the
ratings of change being obtained at the expense of low
specificity.
Discussion
This study provides empirical data to support previous
discussions of the methodological advantages and disad-
vantages of patient global ratings of change and patient
global ratings of concept for interpreting PRO score
change [4]. This study included osteoporosis patients
who were expected to remain stable in terms of the con-
cept of interest over a two-week period from study base-
line (no recent fracture patients) and those who were
expected to report improvement on the concept of
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interest over 12 weeks (recent fracture patients). There-
fore the study design allowed for an evaluation of the
performance of patient global ratings of change and pa-
tient global ratings of concept for interpreting both
patient stability and improvement in the PRO of interest,
the OPAQ-PF.
Substantial disparities were found between the per-
formance of the ratings of change and ratings of concept
Table 2 Mean OPAQ-PF total scores at baseline, change scores, and effect sizes at weeks 2 (no recent fracture patients) and 12
(recent fracture patients) by changes in patient global ratings of concept at weeks 2 and 12
No recent fracture patients (N = 105) Recent fracture patients (N = 34)
Change in rating
of concept
Baseline 2 weeks Effect sizea for
OPAQ-PF change
Baseline 12 weeks Effect sizea for









3 or 4 0 - - - 2 63.3 (51.9) 22.7 (71.7) 0.44
2 4 80.0 (26.8) 2.33 (24.2) 0.09 4 42.3 (6.00) 37.7 (16.1) 6.28
1 12 84.6 (14.5) 2.33 (12.0) 0.16 12 55.9 (20.6) 19.0 (18.0) 0.92
0 72 81.1 (22.6) −2.54 (8.89) −0.11 15 64.4 (28.6) 3.91 (21.7) 0.14
−1 14 83.9 (22.3) −3.33 (8.57) −0.15 1 69.3 −9.33 -
−2 3 69.6 (30.3) −6.49 (13.1) −0.21 0 - - -
−3 or −4 0 - - - 0 - - -
K-W test p-value 0.475 0.069
Linear trend p-value (departures
from linear trend)
0.079 (0.848) 0.015 (0.606)
rs(p-value) 0.152 (0.122) 0.464 (0.006)
Physical Positions
3 or 4 0 - - - 3 38.2 (10.1) 50.2 (27.4) 4.97
2 5 61.3 (35.1) 4.80 (17.6) 0.14 6 44.4 (10.3) 35.8 (13.4) 3.48
1 16 83.5 (17.2) 0.00 (5.74) 0.0 7 61.7 (17.4) 14.3 (18.5) 0.82
0 65 82.4 (21.8) −1.83 (10.2) 0.08 11 59.2 (34.4) 3.39 (22.1) 0.10
−1 17 81.0 (21.2) −6.40 (9.80) −0.31 7 77.0 (15.7) −4.19 (13.9) −0.27
−2 2 94.0 (6.60) −4.00 (7.54) −0.61 0 - - -
−3 or −4 0 - - - 0 - - -
K-W test p-value 0.150 <0.005
Linear trend p-value(departures from
linear trend)
0.021 (0.840) <0.001 (0.763)
rs(p-value) 0.247 (0.011) 0.749 (<.001)
Transfersb
3 or 4 1 73.3 (−) 6.67 (−) - 2 44.0 (1.89) 38.7 (26.4) 20.5
2 4 64.7 (23.4) 1.33 (16.7) 0.12 7 45.2 (15.3) 37.0 (22.5) 2.42
1 17 79.1 (15.5) 0.78 (6.00) 0.05 4 65.7 (31.2) 13.3 (28.9) 0.43
0 62 84.8 (22.4) −1.96 (10.3) −0.09 15 64.4 (29.9) 2.58 (20.5) 0.09
−1 17 78.2 (24.4) −4.91 (9.99) −0.20 3 64.0 (13.1) 14.2 (16.9) 0.83
−2 2 76.7 (2.83) −17.3 (5.66) −6.11 1 40.0 (−) 10.7 (−) -
−3 or −4 0 - - - 0 - - -
K-W test 0.015 0.063
Linear trend p-value(departures from
linear trend)
0.010 (0.742) 0.005 (0.332)
rs(p-value) 0.318 (0.001) 0.503 (0.003)
Data are shown for patients with data at each two assessments
aCohen’s d effect size = mean change / baseline SD
bN = 103 (no recent fracture) N = 32 (recent fracture)
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in terms of level of change identified, but the ratings of
concept consistently outperformed the ratings of change
in terms of better informing interpretation of change in
OPAQ-PF scores. Thus, while the patients without
recent fracture were more likely to report stability (no
change) two weeks after baseline on the ratings of
change items, any changes which were reflected in the
change in OPAQ-PF scores were more likely to be
Table 3 Mean OPAQ-PF total scores at baseline, change scores, and effect sizes at weeks 2 (no recent fracture patients and 12
(recent fracture patients) by patient global ratings of change at weeks 2 and 12
No recent fracture patients (N = 105) Recent fracture patients (N = 34)
Rating of change Baseline 2 weeks Effect sizea for
OPAQ-PF change
Baseline 12 weeks Effect sizea for









Much better 4 91.3 (7.96) −0.67 (4.93) −0.08 12 70.4 (25.8) 19.9 (27.9) 0.77
Moderately better 5 89.6 (11.2) −4.53 (5.47) −0.40 6 42.7 (20.4) 29.1 (19.4) 1.43
A little better 4 89.7 (9.70) −8.00 (13.5) −0.82 3 61.3 (26.0) −1.78 (47.2) −0.07
No change 79 82.5 (22.1) −0.38 (9.23) −0.02 8 51.3 (27.5) 6.83 (10.7) 0.25
A little worse 10 77.3 (14.0) −10.7 (14.4) −0.76 3 64.9 (21.6) −4.89 (16.0) −0.23
Moderately worse 2 38.7 (17.0) −1.33 (11.3) −0.08 2 56.0 (3.8) 12.7 (23.6) 3.34
Much worse 1 22.7 (−) −14.7 (−) - - - - -
K-W test p-value 0.148 0.24
Linear trend p-value (departures
from linear trend)
0.33 (0.033) 0.086 (0.49)
rs (p-value) −0.082 (0.405) 0.322 (0.064)
Physical Positions
Much better 3 92.0 (9.61) 1.33 (3.53) 0.14 12 70.6 (25.6) 21.9 (28.7) 0.86
Moderately better 3 89.8 (14.4) −5.78 (6.84) −0.40 3 38.2 (6.30) 38.7 (16.2) 6.14
A little better 6 91.6 (6.29) −8.44 (8.95) −1.34 4 39.3 (17.7) 19.7 (11.4) 1.11
No change 81 82.7 (21.6) −0.87 (9.58) −0.04 8 52.5 (28.5) 8.67 (8.58) 0.30
A little worse 8 77.3 (12.6) −7.83 (16.0) −0.62 7 66.3 (16.6) −7.62 (26.2) −0.46
Moderately worse 3 40.9 (12.6) 0 (8.33) 0.0 - - - -
Much worse 1 22.7 (−) −14.7 (−) - - - - -
K-W test p-value 0.224 0.033
Linear trend p-value (departures
from linear trend)
0.631 (0.131) 0.007 (0.310)
rs (p-value) 0.042 (0.673) 0.447 (0.008)
Transfersb
Much better 3 89.3 (14.1) −2.67 (9.61) −0.19 12 65.1 (26.3) 24.6 (29.2) 0.94
Moderately better 3 90.7 (8.74) −3.56 (3.36) −0.41 3 42.2 (5.39) 33.8 (7.81) 6.27
A little better 5 94.7 (4.62) −8.80 (9.96) −1.90 4 50.3 (30.6) 1.33 (39.0) 0.04
No change 88 82.2 (21.3) −0.87 (9.31) −0.04 11 61.9 (26.9) 6.30 (14.4) 0.10
A little worse 3 70.7 (7.42) −18.2 (23.3) −2.45 2 59.3 (27.3) 3.33 (10.4) 0.12
Moderately worse 2 38.7 (17.0) −1.33 (11.3) −0.08 1 58.7 −4.0 -
Much worse 1 22.7 (−) 14.7 (−) - - - - -
K-W test p-value 0.304 0.133
Linear trend p-value (departures
from linear trend)
0.655 (0.026) 0.030 (0.740)
rs (p-value) 0.028 (0.777) 0.426 (0.013)
Data are shown for patients with data at each two assessments
aCohen’s d effect size = mean change / baseline SD
bN = 33 (recent fracture)
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identified by the ratings of concept: correlations with
OPAQ-PF score change at two weeks were higher for
ratings of concept than ratings of change. Similarly,
although the recent fracture patients were more likely to
report substantial improvement on the ratings of change,
in line with expected change, correlations with OPAQ-
PF score change were stronger and more likely to be sta-
tistically significant for changes in the ratings of concept
than the ratings of change. Thus, OPAQ-PF change
scores were more likely to be different between the rat-
ings of concept change than the ratings of change cat-
egories across both time points: effect sizes for OPAQ-
PF score change generally increased linearly by level of
ratings of concept change but showed an irregular
pattern for ratings of change. The ROC curves also indi-
cated that in terms of relative balance between sensitiv-
ity and specificity and the overall AUC, the OPAQ-PF
had stronger discriminating properties in terms of the
ratings of concept than those based on the ratings of
change. Results are stronger for the week 12 data be-
cause of the greater likelihood of stability at week 2 ra-
ther than change.
It is important to note that as the patients completed
both measures of change and concept on the same occa-
sions the discrepancies identified in this analysis reflect
differences in the way in which patients completed the
ratings of change compared with the ratings of concept.
At week 12, patients were required to think back 12
weeks to their baseline visit in order to evaluate change
in the concept of interest (e.g. mobility). It is likely to
have been a challenge for participants to think back ac-
curately over this time period in order to be able to rate
their change. Correlation analysis conducted in this
study indicates a systematic bias in patient ratings of
change. The greater correlation between ratings of
change and ratings of concept at the same time-point,
compared with correlations with baseline ratings of con-
cept suggest patients are influenced more by how they
feel currently than by an accurate assessment of how
they felt previously. This is consistent with previous re-
ports of retrospective recall of change at follow-up being
positively correlated with concurrent PRO scores and ei-
ther un-correlated or positively correlated with baseline
scores [8, 15]. These indicate that respondents with good
health at follow-up are more likely to assume that their
health has recently improved, and respondents with
poor health are more likely to assume that it has
worsened [16].
There are issues associated with osteoporosis which
are likely to increase error measurement in the patient’s
self-reports. Specifically, the length of recall required in
order to capture change associated with the healing of a
fracture meant that patients were asked to recall over a
substantial period of time (12 weeks) for the global rat-
ing of change item. Given the older age of osteoporosis
patients, this length of recall may be a specific challenge
for these patients leading to greater recall inaccuracies
than may be experienced in other indications. It was for
this reason that the global ratings of change at 24-weeks
asked about change since the last visit rather than from
baseline. The significant comorbidity experienced in
osteoporosis may also influence the reporting on both
the ratings of concept and ratings of change, as patients
may find it hard to separate physical function impacts
Table 4 ROC statistics for a 1-point change in rating of concept and rating of change at weeks 2 (no recent fracture patients) and
12 (recent fracture patients): Area Under the Curve (AUC), Best Cut Point (BCP) with values of sensitivity (Se) and specificity (Sp) of
OPAQ-PF change scores
No recent fracture patients Recent fracture patients
Week 2 Week 12
N (%) AUC (95 % CI) BCP (Se, Sp) N (%) AUC (95 % CI) BCP (Se, Sp)
Ratings of change
Mobility 13(12) 0.41 (0.26-0.57) p = 0.31 −6.67(0.77, 0.27) 21(62) 0.71 (0.54, 0.89) p = 0.038 10.67(0.71, 0.69)
Physical positions 12(11) 0.37 (0.22-0.52) p = 0.14 −6.67(0.75, 0.27) 19(56) 0.78 (0.62-0.94) p < 0.001 10.67(0.79, 0.73)
Transfers 11(11) 0.37 (0.21-0.53) p = 0.16 −6.67(0.73, 0.27) 19(56) 0.74 (0.56-0.91) p = 0.022 10.67(0.79,0.71)
Mean AUC/BCP Mean (Se, Sp) 0.38 −6.67(0.75, 0.27) 0.74 10.67(0.76, 0.71)
Overall mean AUC Mean (Se, Sp) 0.56 (range = 0.37 to 0.78) (0.76, 0.49)
Ratings of concept
Mobility 16(15) 0.60 (0.43-0.78) p = 0.19 2.0(0.50, 0.79) 18(53) 0.74 (0.57-0.91) p = 0.016 10.67(0.78, 0.69)
Physical positions 21(20) 0.63 (0.49-0.77) p = 0.075 1.33(0.48, 0.23) 16(47) 0.87 (0.75-1.00) p < 0.001 12.0(0.88, 0.78)
Transfers 22(21) 0.68 (0.55-0.82) p = 0.008 0.67(0.59, 0.77) 13(41) 0.82 (0.66-0.98) p = 0.002 12.67(0.85, 0.68)
Mean AUC/BCP>Mean (Se, Sp) 0.64 1.33(0.52, 0.60) 0.81 11.78(0.84, 0.72)
Overall mean AUCMean (Se, Sp) 0.73 (range = 0.60 to 0.87) (0.68, 0.66)
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that are a specific consequence of osteoporosis from
those associated with comorbidities. Specifically, over a
third of the patients with a recent fracture had osteo-
arthritis. The global items asked patients to report their
difficulty with or change in mobility, physical positions
and transfers ‘due to your osteoporosis’ and the extent
to which patients were able to attribute their experience
to their osteoporosis or osteoarthritis was not evaluated
in this analysis. It is possible that change in difficulty
with mobility, physical positions and transfers may have
occurred due to the patient’s osteoarthritis, which might
have presented a reporting challenge to these patients or
meant that these patients were not as stable as the ana-
lysis has understood them to be.
This study had several limitations, most notably that
only those in the relatively small ‘recent fracture’ group
in this study were hypothesized to change, and therefore
there were few subjects in each of the relevant categories
of change. This leads to instability of and uncertainty
around the estimates calculated. This study was not
purpose-designed to evaluate the research question pre-
sented, and instead represents secondary analysis of data
that was designed to evaluate the psychometric measure-
ment properties of the OPAQ-PF reported elsewhere
[10]. This study is therefore limited to providing an indi-
cation of the relative performance of the two ap-
proaches. The findings from this study need to be
confirmed in a purpose-designed larger-scale analysis
before firm conclusions can be drawn regarding the stat-
istical performance of patient global ratings of concept
compared with patient global ratings of change.
Further limitations to the study include the fact that
the sample was more suitable for evaluating stability or
change in terms of improvement rather than decline. Al-
though the ratings of change and ratings of concept
allowed for report of decrement, the validation study in-
clusion criteria were designed to identify patients who
were anticipated to remain stable (with no recent frac-
ture history) or improve (following a recent fracture).
Further work is required in order to determine whether
the benefit of ratings of concept over ratings of change
reported here are maintained in a study which sees pa-
tients experiencing decrement in the concept of interest.
Secondly, no overall physical function global ratings of
concept and change items were developed to match
conceptually the final uni-dimensional structure of the
OPAQ-PF; instead three patient global ratings of con-
cept and equivalent ratings of change were developed to
reflect the three content areas of the OPAQ-PF (mobil-
ity, physical positions and transfers). However, this did
provide more granular results than would be possible
with a single global item. Following completion of the
data collection on which this analysis is based, the
OPAQ-PF response option ‘completely avoided doing
this’ was subsequently changed to ‘unable to do’ in line
with feedback from the regulatory authorities. Finally,
the impact of response shift has not been considered,
where an individual’s criteria for the construct of inter-
est changes during the course of illness and treatment,
possibly leading to a modification of their internal stan-
dards, values and conceptualization of the target con-
struct [17]. Response shift is an issue for patients
reporting on ratings of concept as much as it is for
those reporting on ratings of change, adding unmeas-
ured variability not considered in our results.
Conclusion
This study provides initial empirical support for
methodological and regulatory recommendations to
use patient global ratings of concept when evaluating
interpretation of change for PRO instruments in stud-
ies evaluating treatment effects. It provides further
evidence for the role of present state bias in leading
patients systematically to overestimate their degree of
improvement (or worsening) when using patient glo-
bal ratings of change. These findings warrant being
confirmed in a purpose-designed larger scale study.
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